Leukemic Phase of ALCL

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia

NCT01488162 ·Status: COMPLETED

R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia

NCT00504491 ·Status: WITHDRAWN ·Phase: PHASE2

Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL

NCT03559413 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

NCT01455051 ·Status: COMPLETED ·Phase: PHASE2

Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia

NCT00934986 ·Status: COMPLETED ·Phase: NA

Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk

NCT06475469 ·Status: RECRUITING ·Phase: NA

Identification of Occupational Exposures in Acute Hematologic Malignancy

NCT03316209 ·Status: COMPLETED

Treatment of Localized Low Grade Lymphomas

NCT00536458 ·Status: COMPLETED ·Phase: PHASE3

A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT07044050 ·Status: RECRUITING ·Phase: PHASE1

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

NCT02285062 ·Status: COMPLETED ·Phase: PHASE3

A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL

NCT00858117 ·Status: COMPLETED ·Phase: PHASE2

Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.

NCT00429065 ·Status: UNKNOWN

Cyclophosphamide and Alemtuzumab In Lymphoma

NCT03132584 ·Status: TERMINATED ·Phase: PHASE1

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

NCT05025800 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia

NCT01849939 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

NCT04245839 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma

NCT01290120 ·Status: COMPLETED ·Phase: PHASE2

A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma

NCT04827004 ·Status: UNKNOWN ·Phase: PHASE2

Lymphoma in the Orbit

NCT01302912 ·Status: UNKNOWN

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

NCT05948943 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia

NCT02618109 ·Status: TERMINATED ·Phase: PHASE4

Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America

NCT02559583 ·Status: COMPLETED

The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)

NCT00444912 ·Status: COMPLETED ·Phase: PHASE2

Personalized Therapy of Precursor Lymphoid Neoplasms

NCT01665001 ·Status: UNKNOWN ·Phase: PHASE2

The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

NCT00441025 ·Status: TERMINATED ·Phase: PHASE2